NMRA

The most impactful stock event was the announcement on June 15, 2026, that navacaprant failed Phase 3 studies for major depressive disorder, leading to its discontinuation and a 35% workforce reduction. This caused NMRA's stock price to fall by about 45% and underperform the S&P500 Index by -75.15% over the past six months. As of late September 2026, shares were trading -64.32% below their 200-day moving average and had moved by -61.58% over the past 365 days, with a year-to-date change of -73.20%. Other events include the reporting of Q2 2026 financial results and a business update on August 14, 2026, favorable NMRA-215 toxicology results with planned clinical advancement reported on July 27, 2026, and Q1 2026 financial results and business update on May 7, 2026, which noted KOASTAL-2 and -3 studies were on track.